Published 2025-01-01
“…Lingzhao Zhang,1,2 Jiangshan Pi,1,2 Jinsong Wang,3 Jingsi Chen,1 Yunxuan Zhang,1,2 Jie Li,4 Lingling Wang,1,2 Yue Li,1,2 Anwei Chen,1 Xiaoyan Luo,1,5,* Hua Wang1,2,5,* 1Department of Dermatology, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 2Chongqing Key Laboratory of Child Infection and Immunity, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China; 3Department of Gastroenterology, Chongqing Dongnan Hospital, Chongqing, People’s Republic of China; 4Department of Pediatrics, Chongqing
Jiangjin District Maternal and Child Health Hospital, Chongqing, People’s Republic of China; 5Ministry of Education Key Laboratory of Child Development and Disorders, Children’s Hospital of Chongqing Medical University, Chongqing, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hua Wang; Xiaoyan Luo, Department of Dermatology, Children’s Hospital of Chongqing Medical University, No. 136 Zhongshan Second Road, Yuzhong District, Chongqing, 400015, People’s Republic of China, Tel +8615123380348, Email huawang@hospital.cqmu.edu.cn; xyluo@hospital.cqmu.edu.cnBackground: Dupilumab is a safe and effective treatment for moderate to severe atopic dermatitis (AD), but real-world data in pediatric patients in China are limited. …”
Get full text
Article